CN103269698B - 用于施用活性物质的经皮治疗系统 - Google Patents

用于施用活性物质的经皮治疗系统 Download PDF

Info

Publication number
CN103269698B
CN103269698B CN201180059614.1A CN201180059614A CN103269698B CN 103269698 B CN103269698 B CN 103269698B CN 201180059614 A CN201180059614 A CN 201180059614A CN 103269698 B CN103269698 B CN 103269698B
Authority
CN
China
Prior art keywords
layer
therapeutic system
active material
transcutaneous therapeutic
active substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180059614.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN103269698A (zh
Inventor
布丽塔·朗格尔
比约恩·舒拉德
海克·普林茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Luye Pharma AG
Original Assignee
Acino AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acino AG filed Critical Acino AG
Priority to CN202110438860.3A priority Critical patent/CN113244199A/zh
Priority to CN201710451001.1A priority patent/CN107412202A/zh
Publication of CN103269698A publication Critical patent/CN103269698A/zh
Application granted granted Critical
Publication of CN103269698B publication Critical patent/CN103269698B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201180059614.1A 2010-12-14 2011-12-14 用于施用活性物质的经皮治疗系统 Active CN103269698B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202110438860.3A CN113244199A (zh) 2010-12-14 2011-12-14 用于施用活性物质的经皮治疗系统
CN201710451001.1A CN107412202A (zh) 2010-12-14 2011-12-14 用于施用活性物质的经皮治疗系统

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10194968.3A EP2468274B1 (de) 2010-12-14 2010-12-14 Transdermales therapeutisches System zur Verabreichung eines Wirkstoffs
EP10194968.3 2010-12-14
PCT/EP2011/072812 WO2012080365A1 (de) 2010-12-14 2011-12-14 Transdermales therapeutisches system zur verabreichung eines wirkstoffs

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN201710451001.1A Division CN107412202A (zh) 2010-12-14 2011-12-14 用于施用活性物质的经皮治疗系统
CN202110438860.3A Division CN113244199A (zh) 2010-12-14 2011-12-14 用于施用活性物质的经皮治疗系统

Publications (2)

Publication Number Publication Date
CN103269698A CN103269698A (zh) 2013-08-28
CN103269698B true CN103269698B (zh) 2017-07-14

Family

ID=43836835

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201180059614.1A Active CN103269698B (zh) 2010-12-14 2011-12-14 用于施用活性物质的经皮治疗系统
CN202110438860.3A Pending CN113244199A (zh) 2010-12-14 2011-12-14 用于施用活性物质的经皮治疗系统
CN201710451001.1A Pending CN107412202A (zh) 2010-12-14 2011-12-14 用于施用活性物质的经皮治疗系统

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202110438860.3A Pending CN113244199A (zh) 2010-12-14 2011-12-14 用于施用活性物质的经皮治疗系统
CN201710451001.1A Pending CN107412202A (zh) 2010-12-14 2011-12-14 用于施用活性物质的经皮治疗系统

Country Status (25)

Country Link
US (2) US10660863B2 (https=)
EP (2) EP2468274B1 (https=)
JP (1) JP6043296B2 (https=)
KR (1) KR101842309B1 (https=)
CN (3) CN103269698B (https=)
AU (2) AU2011343363B2 (https=)
BR (1) BR112013014616B1 (https=)
CA (2) CA2817461C (https=)
CY (2) CY1116638T1 (https=)
DK (2) DK2468274T3 (https=)
EA (1) EA026520B1 (https=)
ES (2) ES2545094T3 (https=)
HK (1) HK1243336A1 (https=)
HR (2) HRP20201880T1 (https=)
HU (2) HUE027916T2 (https=)
LT (1) LT2651410T (https=)
MX (1) MX345344B (https=)
MY (1) MY183873A (https=)
PL (2) PL2468274T3 (https=)
PT (2) PT2468274E (https=)
RS (2) RS54173B1 (https=)
SI (2) SI2468274T1 (https=)
SM (2) SMT202000638T1 (https=)
WO (1) WO2012080365A1 (https=)
ZA (1) ZA201303965B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102012000369A1 (de) * 2012-01-11 2013-07-11 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System mit Cholinesterase-Hemmer
DE102012016317A1 (de) 2012-08-14 2014-02-20 Jenabatteries GmbH Redox-Flow-Zelle zur Speicherung elektrischer Energie
CN104582693A (zh) * 2012-08-15 2015-04-29 道康宁公司 多层药物递送系统
WO2014111790A2 (en) * 2013-01-15 2014-07-24 Zydus Technologies Limited Stable transdermal pharmaceutical drug delivery system comprising rivastigmine
US20240082065A1 (en) * 2016-07-08 2024-03-14 Moteah Williams Waterproof and transparent wound barrier and method of manufacturing same
CN109640976B (zh) 2016-08-22 2023-10-17 救急药品工业株式会社 贴附剂
US12290501B2 (en) * 2017-07-19 2025-05-06 Teikoku Seiyaku Co., Ltd. Rivastigmine-containing transdermal absorption preparation
DE102018120506A1 (de) * 2017-10-20 2019-04-25 Amw Gmbh Stabilisiertes transdermales Darreichungssystem
DE102017127433A1 (de) * 2017-11-21 2019-05-23 Lts Lohmann Therapie-Systeme Ag TTS auf Basis von klebenden Weichmacher-Polymer-Matrices
US20210038532A1 (en) * 2018-03-13 2021-02-11 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system comprising a silicone acrylic hybrid polymer
WO2019220697A1 (ja) * 2018-05-17 2019-11-21 パナソニックＩｐマネジメント株式会社 生体貼付け用選択透過膜、経皮吸収キットおよび美容方法
DK3513965T3 (da) 2018-08-08 2022-07-25 Danapak Flexibles As Forbedrede film og laminater til anvendelse i pakning af reaktive forbindelser
KR102710072B1 (ko) 2018-08-31 2024-09-24 에스케이케미칼 주식회사 장기 투여용 리바스티그민 패취
KR102823139B1 (ko) 2018-08-31 2025-06-19 에스케이케미칼 주식회사 장기 투여용 리바스티그민 패취
BR112021023509A2 (pt) * 2019-07-09 2022-01-18 Lts Lohmann Therapie Systeme Ag Sistema terapêutico transdérmico compreendendo uma camada contendo o agente ativo compreendendo um polímero acrílico e uma camada de contato com a pele compreendendo um adesivo de gel de silicone
CN113616625B (zh) * 2021-08-26 2023-05-30 大连科翔科技开发有限公司 一种卡巴拉汀的长效透皮贴剂
DE102021128912A1 (de) * 2021-11-05 2023-05-11 Lts Lohmann Therapie-Systeme Ag. Okklusives pflaster mit flexibler backing

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1354654A (zh) * 1999-04-22 2002-06-19 罗曼治疗系统股份公司 包括经中和的压力敏感性丙烯酸酯粘附剂的穿皮治疗系统
CN101312717A (zh) * 2005-12-01 2008-11-26 诺瓦提斯公司 透皮治疗系统
CN101460156A (zh) * 2006-05-08 2009-06-17 帝国制药株式会社 抗痴呆药的经皮吸收制剂

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL195004C (nl) 1987-03-04 2003-11-04 Novartis Ag Fenylcarbamaat bevattend farmaceutisch preparaat.
CA2142871A1 (en) * 1992-08-25 1994-03-03 Jesus Miranda Printed transdermal drug delivery device
JPH0912448A (ja) * 1995-04-28 1997-01-14 Read Chem Kk 薬物放出制御型経皮吸収製剤
GB9800526D0 (en) 1998-01-12 1998-03-11 Ciba Geigy Ag Organic compounds
US6348210B1 (en) * 1998-11-13 2002-02-19 Alza Corporation Methods for transdermal drug administration
DE10033853A1 (de) 2000-07-12 2002-01-31 Hexal Ag Transdermales therapeutisches System mit hochdispersem Siliziumdioxid
DE10103860B4 (de) * 2001-01-30 2004-12-23 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System für die Verabreichung carboxylgruppenhaltiger, nichtsteroidaler Antiphlogistika, sowie Verfahren zu seiner Herstellung
DE10141652B4 (de) 2001-08-24 2011-04-07 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System auf der Basis von Polyacrylat-Haftklebern ohne funktionelle Gruppen und seine Verwendung
DE10141650C1 (de) * 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
US8252319B2 (en) * 2004-10-21 2012-08-28 Durect Corporation Transdermal delivery system for sufentanil
SI1814531T1 (sl) * 2004-10-21 2010-10-29 Durect Corp Transdermalni dostavni sistem
CA2634975A1 (en) * 2005-12-30 2007-07-12 Coloplast A/S A layered adhesive construct having a mouldable layer as skin contact surface
CN101304735A (zh) * 2006-01-12 2008-11-12 Lts勒曼治疗系统股份公司 用于挥发性和/或热不稳定的物质的经皮治疗体系
US9248104B2 (en) 2006-08-17 2016-02-02 Core Tech Solutions, Inc. Transdermal methods and systems for treating Alzheimer's disease
DE102006054731B4 (de) * 2006-11-21 2013-02-28 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
WO2009009651A1 (en) 2007-07-10 2009-01-15 Agile Therapeutics, Inc. Dermal delivery device with ultrasonic weld
WO2009026135A2 (en) * 2007-08-17 2009-02-26 Alza Corporation Controlled transdermal bisoprolol delivery system
US9155725B2 (en) * 2008-02-27 2015-10-13 Hisamitsu Pharmaceutical Co., Inc. Adhesive skin patch and packaged product
US20090291127A1 (en) * 2008-05-21 2009-11-26 Jianye Wen Transdermal anti-dementia active agent formulations and methods for using the same
JP2010126450A (ja) * 2008-11-25 2010-06-10 Lintec Corp 経皮吸収貼付剤
BR112012017168B1 (pt) * 2009-12-22 2022-03-15 Luye Pharma Ag Sistemas terapêuticos transdérmicos, seu processo de preparação, e usos de um polímero ou copolímero

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1354654A (zh) * 1999-04-22 2002-06-19 罗曼治疗系统股份公司 包括经中和的压力敏感性丙烯酸酯粘附剂的穿皮治疗系统
CN101312717A (zh) * 2005-12-01 2008-11-26 诺瓦提斯公司 透皮治疗系统
CN101460156A (zh) * 2006-05-08 2009-06-17 帝国制药株式会社 抗痴呆药的经皮吸收制剂

Also Published As

Publication number Publication date
CA3065240C (en) 2022-02-15
ZA201303965B (en) 2014-09-25
JP2014503523A (ja) 2014-02-13
AU2011343363B2 (en) 2017-06-08
AU2011343363A1 (en) 2013-06-20
CY1123712T1 (el) 2022-03-24
EP2651410A1 (de) 2013-10-23
SI2651410T1 (sl) 2021-01-29
LT2651410T (lt) 2020-12-28
MX345344B (es) 2017-01-26
PT2651410T (pt) 2020-12-15
US10660863B2 (en) 2020-05-26
PT2468274E (pt) 2015-09-21
EP2651410B1 (de) 2020-10-14
CA3065240A1 (en) 2012-06-21
US20200289426A1 (en) 2020-09-17
CY1116638T1 (el) 2017-03-15
BR112013014616A2 (pt) 2016-09-20
BR112013014616B1 (pt) 2021-12-21
CN113244199A (zh) 2021-08-13
HRP20150881T1 (hr) 2015-09-25
EP2468274A1 (de) 2012-06-27
DK2651410T3 (da) 2020-11-02
CA2817461C (en) 2020-02-25
HUE027916T2 (en) 2016-11-28
HK1243336A1 (zh) 2018-07-13
ES2545094T3 (es) 2015-09-08
AU2017213569B2 (en) 2019-04-11
KR20130129988A (ko) 2013-11-29
RS61155B1 (sr) 2020-12-31
WO2012080365A1 (de) 2012-06-21
US20140323996A1 (en) 2014-10-30
MX2013005581A (es) 2013-08-26
CA2817461A1 (en) 2012-06-21
EA201300704A1 (ru) 2014-01-30
DK2468274T3 (en) 2015-08-31
ES2836483T3 (es) 2021-06-25
CN103269698A (zh) 2013-08-28
KR101842309B1 (ko) 2018-03-26
JP6043296B2 (ja) 2016-12-14
SMT201500184B (it) 2015-09-07
SMT202000638T1 (it) 2021-01-05
PL2468274T3 (pl) 2015-11-30
EP2468274B1 (de) 2015-07-01
EA026520B1 (ru) 2017-04-28
HUE052137T2 (hu) 2021-04-28
PL2651410T3 (pl) 2021-03-08
SI2468274T1 (sl) 2015-10-30
RS54173B1 (sr) 2015-12-31
MY183873A (en) 2021-03-17
HRP20201880T1 (hr) 2021-02-05
AU2017213569A1 (en) 2017-08-31
CN107412202A (zh) 2017-12-01

Similar Documents

Publication Publication Date Title
CN103269698B (zh) 用于施用活性物质的经皮治疗系统
JP6083734B2 (ja) リバスチグミンまたはその誘導体を投与するための経皮治療システム
CA1261267A (en) Transdermal system for timolol
US20110111013A1 (en) Transdermal therapeutic system for administration of fentanyl or an analogue thereof
US10076502B2 (en) Transdermal therapeutic system for administering rivastigmine or derivatives thereof
HK1187247A (en) Transdermal therapeutic system for administering an active substance
HK1187247B (en) Transdermal therapeutic system for administering an active substance
AU2013242824A1 (en) Transdermal therapeutic system for administration of fentanyl or an analog thereof
HK1170945A (en) Transdermal therapeutic system for administering rivastigmine or derivatives thereof
HK1170945B (en) Transdermal therapeutic system for administering rivastigmine or derivatives thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: German Missbach

Applicant after: Green leaf Pharmaceutical Co., Ltd.

Address before: German Missbach

Applicant before: Acino AG

GR01 Patent grant
GR01 Patent grant